Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials

Pavletić, Steven Z.; Lee, S J; Socié, Gèrard; Vogelsang, G. B.

doi:10.1038/sj.bmt.1705490

Cited by 89 publications

(66 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Arthralgia and arthritis with synovitis are rare features of cGVHD, being occasionally associated with the presence of autoantibodies. 2 FISH analysis for sex chromosome in sex-mismatched transplant has been proposed for the genotypic characterization of mononuclear cells infiltrate, supporting cGVHD diagnosis.…”

mentioning

confidence: 99%

Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT

Nozzoli

Guidi

Paglierani

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

mentioning

confidence: 99%

Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT

Nozzoli

Guidi

Paglierani

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

“…17 Disease evaluation by FDG-PET Disease evaluation by FDG-PET was performed before and after HD-PAM. PET images were acquired 60 min after i.v.…”

Section: Allo-sctmentioning

confidence: 99%

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant

Castagna

Crocchiolo

Giordano

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Persistence of disease after salvage therapy among relapsed or refractory Hodgkin lymphoma (HL) patients predicts poor outcome. Here, we report on 41 HL patients with active disease after salvage therapy and who received high-dose melphalan (HD-PAM) and auto-SCT as a bridge to a second autologous or an allogeneic transplantation between 2002 and 2013 at our center. Disease response was based on 18-fluoro-deoxyglucose-positron emission tomography results in all patients. Overall response rate after HD-PAM was 78% and it did not differ among PR or stable/progressive disease patients (P = 1.00). Response was associated with better OS: hazard ratio = 0.32 (95% confidence interval: 0.13-0.77, P = 0.01) irrespective of disease status before HD-PAM. Thirtythree patients (80%) were able to complete the planned treatment, intended as tandem autologous or auto-allo transplant. Hematological and extrahematological toxicity of HD-PAM was manageable, without any treatment-related death. In conclusion, HD-PAM is a valuable therapeutic option in relapsed/refractory HL patients with active disease after salvage therapy, with an impressive 78% overall response rate and 80% rate of proceeding to further transplantation. The present data may be integrated with the growing literature on new drugs in the field of relapsed/refractory HL.

show abstract

“…9 Two subgroups were proposed for aGvHD: I Classic aGvHD (occurring within 100 days of HSCT) II Persistent, recurrent or late aGvHD occurring 4100 days after transplant.…”

Section: Chronic Gvhd and Organ Involvementmentioning

confidence: 99%

“…8 The National Institutes of Health, in June 2005, sponsored a consensus on standardized criteria for the diagnosis and follow-up of cGvHD. 9 A clinical score between 0 and 3 was proposed for all organs/ sites affected by cGvHD: i.e., skin, mouth, eyes, gastrointestinal tract, liver, lung, joints, fascia and genital tract (Table 1).…”

Section: Chronic Gvhd and Organ Involvementmentioning

confidence: 99%

Non-endocrine late complications in children after allogeneic haematopoietic SCT

Faraci¹,

Békássy

Fazio³

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials

Cited by 89 publications

References 22 publications

Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT

Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant

Non-endocrine late complications in children after allogeneic haematopoietic SCT

Contact Info

Product

Resources

About